Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asthma
Biotech
Generate plans $425M IPO to bankroll phase 3 asthma trials
Generate:Biomedicines hopes to raise $425 million, with the proceeds needed to bankroll its lead antibody through respiratory disease trials.
James Waldron
Feb 23, 2026 9:42am
Upstream posts Tezspire-like asthma efficacy in phase 2
Feb 11, 2026 7:24am
Amgen exits $400M autoimmune pact after running vast program
Jan 30, 2026 8:55am
Spiro Medical snares $67M series A funding for asthma treatment
Jan 8, 2026 10:50am
Foresee offloads clinical-stage MMP-12 inhibitors in $584M deal
Jan 8, 2026 7:45am
Windward pens $700M deal for Qyuns' immunology bispecific
Dec 22, 2025 7:40am
